These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8735685)

  • 1. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis.
    Bendriss EK; Bechtel Y; Bendriss A; Humbert PH; Paintaud G; Magnette J; Agache P; Bechtel PR
    Br J Clin Pharmacol; 1996 May; 41(5):421-4. PubMed ID: 8735685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
    Bechtel YC; Haffen E; Lelouët H; Brientini MP; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2000 Oct; 38(10):467-75. PubMed ID: 11073287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.
    Lelouët H; Bechtel YC; Paintaud G; Brientini MP; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Jan; 39(1):25-32. PubMed ID: 11204934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
    Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine metabolism before and after liver transplantation.
    Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C; Hageman G
    J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
    Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
    Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
    Nyéki A; Buclin T; Biollaz J; Decosterd LA
    Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pantoprazole lacks induction of CYP1A2 activity in man.
    Hartmann M; Zech K; Bliesath H; Steinijans VW; Koch H; Wurst W; Mascher H
    Int J Clin Pharmacol Ther; 1999 Apr; 37(4):159-64. PubMed ID: 10235417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
    Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
    Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
    Rasmussen BB; Brøsen K
    Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
    Relling MV; Lin JS; Ayers GD; Evans WE
    Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases.
    el-Yazigi A; Shabib S; al-Rawithi S; Yusuf A; Legayada ES; al-Humidan A
    J Clin Pharmacol; 1999 Apr; 39(4):366-72. PubMed ID: 10197295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and urine concentrations of 5-methoxypsoralen after oral administration.
    Stolk LM; Westerhof W; Cormane RH; van Zwieten PA
    Br J Dermatol; 1981 Oct; 105(4):415-9. PubMed ID: 7295552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.